- Home
- SLNO
as 12-20-2024 4:00pm EST
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 1.9B | IPO Year: | 2014 |
| Target Price: | $74.83 | AVG Volume (30 days): | 788.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $35.70 - $60.92 | Next Earning Date: | 11-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Soleno Therapeutics Inc. (SLNO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Mackaness James H | SLNO | CHIEF FINANCIAL OFFICER | Oct 1 '24 | Sell | $49.79 | 8,077 | $399,241.39 | 119,172 | |
| Anish Bhatnagar | SLNO | CHIEF EXECUTIVE OFFICER | Oct 1 '24 | Sell | $49.79 | 21,633 | $1,069,306.22 | 721,773 | |
| Yen Kristen | SLNO | SEE REMARKS | Oct 1 '24 | Sell | $49.79 | 3,108 | $153,626.63 | 81,784 | |
| Hirano Patricia C | SLNO | SEE REMARKS | Oct 1 '24 | Sell | $49.79 | 3,108 | $153,626.63 | 109,251 |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
MT Newswires
5 days ago
Soleno Therapeutics Gets $200 Million Debt Financing From Oxford Finance
GlobeNewswire
5 days ago
Soleno Therapeutics Enters Into $200 Million Debt Financing with Oxford Finance LLC
Simply Wall St.
25 days ago
High Growth Tech Stocks to Watch in November 2024
GlobeNewswire
25 days ago
Soleno Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
Pharmaceutical Technology
25 days ago
FDA delays decision of Soleno’s Prader-Willi syndrome drug
BioPharma Dive
25 days ago
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
GuruFocus.com
a month ago
Soleno Tumbles 17% as FDA Extends Review Timeline for Prader-Willi Treatment
MT Newswires
a month ago
Soleno Therapeutics Says FDA Extends DCCR NDA Review Citing 'Major Amendment'
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.